Previous Close | 66.26 |
Open | 66.03 |
Bid | 66.08 x 1100 |
Ask | 66.44 x 1800 |
Day's Range | 66.10 - 66.47 |
52 Week Range | 43.39 - 67.00 |
Volume | |
Avg. Volume | 1,133,614 |
Market Cap | 8.977B |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | 123.09 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basisGAAP net loss for the quarter was $7.1 millionGAAP diluted earnings per share (“EPS”) was ($0.05) and non-GAAP diluted EPS was $0.72Non-GAAP adjusted EBITDA was $166.6 million, or 27.5% of net sa
AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m.
AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basisGAAP net income for the quarter was $15.0 millionGAAP diluted earnings per share (“EPS”) was $0.11 and non-GAAP diluted EPS was $0.60Non-GAAP adjusted EB